About the Company

Bellerophon Therapeutics (NasdaqGM: BLPH) is a clinical-stage biotherapeutics company focused on the development of inhaled nitric oxide (NO) therapy for patients with cardiopulmonary diseases. Bellerophon’s lead development candidate is INOpulse, a drug/device combination product that delivers pulsed NO for the treatment of pulmonary arterial hypertension and pulmonary hypertension related to other conditions. Bellerophon initiated the INOvation Phase III trial to evaluate the benefit of INOpulse in PAH patients on long-term oxygen therapy (LTOT), and expects to report interim results by the end of 2017. A second Phase III withdrawal trial will follow, and its design should allow Bellerophon to reach an NDA filing, and potential marketing approval for INOpulse two years earlier than previously expected and with a drastic reduction in cost. Data from this trial are expected in late 2018. Bellerophon is also developing INOpulse for PH-COPD and PH-IPF, indications with no approved therapies. Results from ongoing Phase II trials in these indications are expected in mid-2017.

Source: LifeSci Capital, LLC research report

Research analyst certification and important disclosures can be found in the full research report. To access the full research report, please click on the link below.

Recent Research